Jefferies raised the firm’s price target on Zymeworks (ZYME) to $42 from $30 and keeps a Buy rating on the shares. The HERIZON-GEA trial evaluating Ziihera showed efficacy against adenocarcinoma, with the data hitting the firm’s bull case, the analyst tells investors in a research note. The firm overall expects Zani will be standard of care in 1L GEA and sees an expansion opportunity.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks price target raised to $37 from $24 at Leerink
- Zymeworks’ Promising Clinical Trial Results and Market Potential Justify Buy Rating
- Zymeworks price target raised to $35 from $22 at Citi
- Midday Fly By: Berkshire takes Alphabet stake, J&J buying cancer drug maker
- Morning Movers: E.W. Scripps surges after report of Sinclair takeover interest